image credit: Unsplash

Univercells’ CDMO Exothera hopes to help scale COVID-19 vaccine manufacturing

With the novel coronavirus continuing its global spread, drugmakers are pouring massive resources into developing targeted therapies and vaccines. Now, a new CDMO from Belgium’s Univercells is hoping its expertise can help drugmakers scale up their manufacturing for a successful shot.

Univercells has launched Exothera, a viral vector CDMO targeting cell and gene therapy and vaccine developers, in a refurbished 161,000-square-foot facility in Jumet, Belgium, the company said Thursday.

Exothera will help companies streamline the development and production of viral vectors through “bespoke” programs, including building custom commercial facilities on site, Univercells said.

Read More on FiercePharma